Please ensure Javascript is enabled for purposes of website accessibility

Here's Why Clovis Oncology Stock Jumped on Wednesday

By Cory Renauer – Updated Apr 20, 2019 at 6:11PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Better-than-expected Rubraca sales were just what investors wanted to see.

What happened

Shares of Clovis Oncology (CLVS 2.59%), a biopharmaceutical company focused on oncology, notched some gains as investors digested the fourth-quarter earnings report. The stock ended Wednesday's session 13.2% higher.

So what 

Although Clovis Oncology didn't quite meet consensus targets during the last three months of 2018, sales of Rubraca are showing signs of life again. A few months ago, the market crushed Clovis shares after the company reported third-quarter Rubraca sales that were $1 million below the previous quarter. Today the stock jumped because fourth-quarter Rubraca sales came in 33% higher than the previous quarter.

person hiding behind a large arrow that's pointing up.

Image source: Getty Images.

Rubraca is a PARP inhibitor that's approved to treat ovarian cancer patients following a relapse, and it shares this indication with Lynparza from and Zejula, both of which have backing from big pharma. Seeing Clovis produce significant sales growth in the fourth quarter gives investors hope that another label expansion will occur before the biotech needs to tap investors again.

Now what

Clovis finished 2018 with $520 million in cash after losing $99.3 million during the fourth quarter. At this rate, Rubraca sales need to keep surging soon, or another share offering could be necessary about one short year from now. 

There's a chance Rubraca sales will perk up as its European launch in the second-line maintenance setting gains steam. Before the end of the year, Clovis expects to submit an application to treat prostate cancer patients after they've failed to respond to hormonal treatments and chemotherapy.

Clovis is also running a phase 3 study with first-line ovarian cancer patients in combination with Opdivo, a popular immunotherapy for a handful of different malignancies. Clovis' outlook isn't terrific right now, but it could be a lot worse. 

Check out the latest Clovis earnings call transcript.

Cory Renauer has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Clovis Oncology, Inc. Stock Quote
Clovis Oncology, Inc.
CLVS
$1.19 (2.59%) $0.03

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
332%
 
S&P 500 Returns
104%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/01/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.